| Domain | SPRY4-specific finding | Evidence strength / source date | Knowledge-base interpretation |
|---|---|---|---|
| Disease definition | **SPRY4-related hypogonadotropic hypogonadism 17 with or without anosmia (HH17)** is a proposed rare genetic form of congenital/isolated GnRH deficiency. Presentations include Kallmann syndrome, normosmic hypogonadotropic hypogonadism, and one adult-onset case. (pqac-00000001, pqac-00000004) | **Limited–moderate:** discovery cohort (2013); single case (2019) | Retain as an **SPRY4-associated CHH entity**, but do not assume every rare heterozygous SPRY4 variant is independently causal. |
| Human genetic evidence | In the foundational study, 386 unrelated CHH probands and 155 controls were screened; 14 probands carried SPRY4 variants. Individual FGF-network candidate genes each accounted for approximately 1–4% of cases. (pqac-00000004, pqac-00000011) | **Moderate association evidence:** candidate-gene case–control study (2013) | Supports association with the CHH spectrum, although variant-level pathogenicity and monogenic sufficiency remain uncertain. |
| **p.Ser241Tyr** | Heterozygous **NM_030964.3:c.722C>A, p.(Ser241Tyr), rs139512218** occurred in Kallmann and normosmic CHH cases, often with variants in **FGFR1, DUSP6,** or **TACR3**. The original study reported control and CHH minor-allele frequencies of 0.6% and 0.5%, respectively; later sources classify it as a VUS. (pqac-00000012, pqac-00000022) | **Conflicting:** human VUS/association evidence (2013–2020); functional evidence (2021) | Do **not** classify as pathogenic solely from case occurrence or in-vitro function. Population frequency, occurrence in controls, and oligogenic context weaken a highly penetrant monogenic interpretation. |
| p.Ser241Tyr function | Tyr241 increased SPRY4 inhibition of **FGF-induced MAPK/ERK signaling** without increasing inhibition of EGF signaling. It reduced WI-38 migration to **9.106 ± 0.305 μm/h**, versus **11.77 ± 0.685 μm/h** for wild type and **12.36 ± 0.781 μm/h** for control, and prolonged approximate doubling time from 10 to 15 days. (pqac-00000013, pqac-00000014, pqac-00000015) | **Moderate functional, low disease-specific:** non-neuronal in-vitro assays (2021) | Supports an **FGF-selective inhibitory hypermorph**, but the assays did not use olfactory ensheathing cells or GnRH neurons and do not establish clinical pathogenicity. |
| **p.Lys177Arg** | Heterozygous **c.530A>G, p.(Lys177Arg)** was reported in a male with Kallmann syndrome, underdeveloped genitalia, and diagnosis at age 13; it was maternally inherited and classified as a **VUS**. (pqac-00000008, pqac-00000021) | **Weak:** single-patient observation without functional validation (2020) | Record as a reported SPRY4 VUS, not a confirmed causal allele. Maternal transmission alone does not establish dominant inheritance or penetrance. |
| **p.Arg53Gln** | Heterozygous **c.158G>A, p.(Arg53Gln)** was the only finding on a 28-locus panel in one man with congenital severe hyposmia, absent olfactory bulbs and tracts, normal puberty, and adult-onset central hypogonadism at age 48. No segregation or functional analysis was reported. (pqac-00000001, pqac-00000002) | **Weak:** single case report (2019) | Treat as a **candidate/VUS-level association**. The olfactory phenotype is supportive, but causality and monogenic sufficiency are unproven. |
| Oligogenicity and inheritance | SPRY4 variants have co-occurred with variants in **FGFR1, DUSP6, TACR3, SEMA3A, PROKR2,** and **NSMF**. In the 2013 European subset, 24 of 124 variant-positive probands had variants in different genes: **19% oligogenicity** (95% CI 12–26%); 23 of 24 combinations included an FGF-network gene. (pqac-00000012) | **Moderate for FGF-network oligogenicity; limited for specific SPRY4 interactions:** 2013–2020 | Model inheritance as potentially **autosomal dominant with incomplete penetrance or oligogenic**, while noting that no definitive SPRY4-specific rule is established. |
| Mechanism | SPRY4 negatively regulates receptor-tyrosine-kinase signaling, especially the **FGF–FGFR–RAS–MAPK/ERK axis**. Excess inhibition by selected variants is hypothesized to impair FGF-dependent olfactory-system development and GnRH-neuron specification, survival, or migration. (pqac-00000010, pqac-00000013, pqac-00000015) | **Moderate pathway evidence; inferred developmental chain:** 2013–2021 | Annotate: SPRY4 hyperactivity → reduced FGF/MAPK signaling → impaired olfactory/GnRH development → anosmia and GnRH deficiency. Label the neuronal steps as **inferred**. |
| Phenotype range | Reported findings include anosmia or hyposmia, olfactory-bulb hypoplasia or aplasia, normosmic CHH, delayed or absent puberty, underdeveloped male genitalia, low libido, infertility, and adult-onset sexual dysfunction. Hearing loss and dental abnormalities occurred among some early carriers, but frequencies are unavailable. (pqac-00000002, pqac-00000003, pqac-00000008) | **Limited:** small numbers, mixed variants, and oligogenic cases (2013–2020) | Use qualitative frequencies such as **reported** or **variable**; reliable SPRY4-specific percentages cannot be calculated. |
| Diagnostics | Diagnosis uses pubertal or adult symptoms, low sex steroids with low or inappropriately normal LH/FSH, exclusion of acquired hypothalamic–pituitary disease, smell testing, and pituitary/olfactory MRI when indicated. CHH panels identify variants of interest in approximately **21–51%** of patients; SPRY4 is less frequently implicated. (pqac-00000002, pqac-00000016, pqac-00000018) | **Strong for general CHH work-up; limited SPRY4-specific utility:** 2019–2024 | Prefer a multigene CHH/Kallmann panel or exome/genome analysis over SPRY4-only testing. Apply ACMG/AMP criteria and assess population frequency, segregation, phenotype, function, and oligogenic context. |
| Treatment | No SPRY4-specific therapy exists. Testosterone improved sexual symptoms in the adult-onset p.Arg53Gln case. General CHH treatment uses sex steroids for pubertal induction or maintenance and **hCG followed by FSH**, combined gonadotropins, or pulsatile GnRH for fertility; testosterone suppresses spermatogenesis. (pqac-00000002, pqac-00000016, pqac-00000019) | **Strong for general CHH; single-case SPRY4 outcome:** 2019–2024 | Management is directed by phenotype and fertility goals, not SPRY4 genotype. Patients pursuing fertility require gonadotropins or GnRH rather than testosterone alone. |
| Epidemiology | No incidence, prevalence, carrier frequency, founder effect, ethnic enrichment, or sex ratio is established for HH17. SPRY4 variants occurred in 14 of 386 probands in the discovery study and 2 of 47 in a Polish cohort, but these are referral-cohort detection rates. (pqac-00000004, pqac-00000020) | **Insufficient:** ascertainment-biased cohorts (2013–2020) | Mark disease-specific epidemiology as **unknown**; do not convert variant-detection proportions into population prevalence. |
| Mouse model | **Spry4-null mice** are viable and fertile, although some die neonatally with mandibular defects and others show growth retardation and polysyndactyly; embryonic fibroblasts have increased FGF-induced ERK activation. Combined Spry2/Spry4 loss is embryonic lethal. (pqac-00000013) | **Moderate developmental/pathway evidence:** knockout findings summarized in 2021 | The knockout models loss of negative regulation, whereas p.Ser241Tyr behaves as an inhibitory hypermorph. Simple Spry4 loss does not reproduce human HH17 convincingly, and olfactory/GnRH phenotypes remain insufficiently characterized. |


*Table: Evidence-grade summary of SPRY4-associated HH17, emphasizing variant uncertainty, oligogenic inheritance, the proposed FGF–MAPK mechanism, and limits of clinical and animal-model evidence.*